Please enable Javascript to use all features and improve your user experience.
EHC 2023
Programme
People
Search
DE
All people
Pranav Gandhi
Sort by Type
Date
Speaker
ePoster
P096
Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial
ePoster
P045
Effect of atogepant on the migraine disability assessment, work productivity and activity impairment questionnaire, and patient global impression of change: results from the ELEVATE trial
ePoster
P051
Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine
Further involvements
ePoster
P019
Benefit-Risk assessment of atogepant vs. placebo in participants with episodic migraine who had prior inadequate response to 2–4 classes of oral preventive treatment: a post-hoc analysis of the ELEVATE trial
ePoster
P022
Atogepant demonstrates early functional and quality of life improvements for the preventive treatment of episodic migraine after prior inadequate response to treatment: results from the ELEVATE trial
ePoster
P096
Atogepant provides early improvements in daily functioning and quality of life: results from the PROGRESS chronic migraine trial
ePoster
P045
Effect of atogepant on the migraine disability assessment, work productivity and activity impairment questionnaire, and patient global impression of change: results from the ELEVATE trial
ePoster
P029
Benefit-Risk assessment based on number needed to treat and number needed to harm: Atogepant vs. calcitonin gene–related peptide monoclonal antibodies
ePoster
P117
Network meta-analysis comparing atogepant vs. CGRP mAbs on headache impact test-6 total scores in episodic and chronic migraine
ePoster
P031
Impact of atogepant on migraine day reduction, response rate, and patient-reported outcomes in participants with episodic migraine and comorbid depressive symptoms: subgroup analysis from the ELEVATE trial
ePoster
P051
Atogepant vs. rimegepant cost per treatment responder analysis for the preventive treatment of episodic migraine
ePoster
P106
Network meta-analysis of atogepant vs. CGRP mAbs on migraine-specific quality of life questionnaire v2.1 in episodic and chronic migraine
© Conventus Congressmanagement & Marketing GmbH
Imprint
Privacy